¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"multiple renal cysts"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple neurofibromatosis
    ´Ù¹ß½Å°æ¼¶À¯Á¾Áõ
  • multiple neuroma
    ´Ù¹ß½Å°æÁ¾
  • multiple paramyoclonus
    ´Ù¹ß±Ù´ë¼º¹ßÀÛ
  • multiple peripheral neuritis
    ´Ù¹ß¸»ÃʽŰ濰
  • multiple personality
    ´ÙÁßÀΰÝ
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • multiple pregnancy
    ´ÙÅÂÀÓ½Å, ¹µÀÓ½Å
  • multiple scattering
    ´ÙÁß»ê¶õ
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple sleep latency test
    ¼ö¸éÀẹ±â¹Ýº¹°Ë»ç
  • multiple subpial transection
    ´Ù¹ß¿¬¸·¹ØÀý´Ü(¼ú)
  • acute renal failure
    ±Þ¼ºÄáÆÏ±â´É»ó½Ç, ±Þ¼º½ÅºÎÀü
  • back pressure renal atrophy
    ¿ª¾ÐÄáÆÏÀ§Ãà, ¿ª¾Ð½ÅÀåÀ§Ãà
  • branchio-oto-renal syndrome
    ¾Æ°¡¹Ì±ÍÄáÆÏÁõÈıº
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • renal scan
    ÄáÆÏ½ºÄµ, ½ÅÀ彺ĵ
  • renal stone
    ÄáÆÏµ¹
  • renal tuberculosis
    ÄáÆÏ°áÇÙ, ½ÅÀå°áÇÙ
  • renal transplantation
    ÄáÆÏÀ̽Ä, ½ÅÀåÀ̽Ä
  • renal function test
    ÄáÆÏ±â´É°Ë»ç, ½ÅÀå±â´É°Ë»ç
  • renal vein thrombosis
    ÄáÆÏÁ¤¸ÆÇ÷ÀüÁõ, ½ÅÀåÁ¤¸ÆÇ÷ÀüÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple personality
    ´ÙÁßÀΰÝ
  • multiple pregnancy
    ¹µÀÓ½Å, ´ÙÅÂÀÓ½Å
  • multiple risk
    ´ÙÁßÀ§Çèµµ
  • multiple scattering
    ´ÙÁß»ê¶õ
  • multiple sclerosis
    ´Ù¹ß°æÈ­Áõ
  • multiple serositis
    ´Ù¹ßÀ帷¿°
  • multiple stratification
    ¹µÁßÃþ
  • multiple trichoepithelioma
    ¿©·¯ÅлóÇÇÁ¾
  • multiple allelic mutation
    ¹µ¸Â¼¶µ¹¿¬º¯ÀÌ
  • multiple compressed tablet
    ´ÙÁß¾ÐÃà¾Ë¾à
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple endocrine neoplasia
    º¹ÇÕ³»ºÐºñ»ù½Å»ý¹°
  • multiple layer tablet
    ´ÙÃþ¾Ë¾à
  • multiple logistic model
    ´ÙÁß·ÎÁö½ºÆ½¸ðÇü
  • multiple pressure method
    ´Ù¾Ð¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • renal
    ½Å(ãì)ÀÇ,½ÅÀå(ãìíô)ÀÇ,½Å¼º(ãìàõ)ÀÇ, ÄáÆÏ(ÀÇ)
  • renal ablation glomerulosclerosis
    ½ÅÀýÁ¦»ç±¸Ã¼°æÈ­Áõ(ãìï·ð¶ÞêϹô÷Ìãûùñø)
  • renal abscess
    ½ÅÇÇÁú³ó¾ç
  • renal abscess
    ½Å³ó¾ç(ãìÒÛåË)
  • renal acidosis
    ½Å¼º»êÁõ.
  • renal acidosis
    ½Å¼º»êÁõ(ãìàõß«ñø)
  • renal adenocarcinoma
    ½Å ¼±¾Ï
  • renal adenoma
    ½Å¼±Á¾
  • renal agenesis
    ½Å¹«¹ßÀ°Áõ(ãìÙíÛ¡ëÀñø)
  • renal albuminuria
    ½Å¼º´Ü¹é´¢(ãìàõÓ±ÛÜèñ).
  • renal albuminuria
    ½Å¼º´Ü¹é´¢(ãìàõÓ±ÛÜèñ)
  • renal amino aciduria
    ½Å¼º ¾Æ¹Ì³ë»ê´¢
  • renal aminoaciduria
    ½Å¼º¾Æ¹Ì³ë»ê´¢(ãìàõ¡­ß«èñ).
  • renal aminoaciduria
    ½Å¼º¾Æ¹Ì³ë»ê´¢(¡­ß«èñ)
  • renal anasarca
    ½Å¼ºÀü½Å¼öÁ¾(ãìàõîïãóâ©ðþ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • multiple cerebral sclerosis
    ¹æ»ç ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(ÒýÛ¡àõÓÞÒàÌãûùñø).
  • multiple cerebral sclerosis
    ´Ù¹ß¼º ´ë³ú°æÈ­Áõ(Û¯ÞÒ¡­ÓÞÒàÌãûùñø)
  • multiple chain
    º¹½Ä(ÜÜãÒ)»ç½½.
  • multiple characters
  • multiple compressed tablet
    ´ÙÁß¾ÐÃàÁ¤Á¦(Òýñìäâõêïüð¥).
  • multiple congenital polyposis
    ´Ù¹ß¼º ¼±Ãµ¼º(¡­à»ô¸àõ) Æú¸³Áõ(¡­ñø)
  • multiple convulsive tic
    ´Ù¹ß¼º °æ·Ã¼º(ÒýÛ¡ àõÌâÕýàõ) ƽ.
  • multiple correlation
    Áß»ó°ü( Ì¡Ë×Ë´).
  • multiple cranial nerve palsy
    ´Ù¹ß¼º ³ú½Å°æ¸¶ºñ(ÒýÛ¡àõÒàãêÌè Ýö).
  • multiple cylindroma
    ´Ù¹ß¼º ¿øÁÖÁ¾
  • multiple deformity
    º¹ÇÕ±âÇü
  • multiple division
    º¹ºÐ¿­(ÜÜÝÂæñ).
  • multiple drug resistance
    ´ÙÁ¦³»¼º
  • multiple drug resistance gene
    º¹ÇÕ¾àÁ¦³»¼ºÀ¯ÀüÀÚ
  • multiple dysplasia (lipochondrodysplasia)
    ¹µÇü¼ºÀå¾Ö (Áö¹æ¿¬°ñÇü¼ºÀå¾Ö)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Renal plexus
    ÄáÆÏ½Å°æ¾ó±â
    [¿¾ ¿ë¾î] ½Å½Å°æÃÑ
  • Renal ganglia
    ÄáÆÏ½Å°æÀý
    [¿¾ ¿ë¾î] ½Å½Å°æÀý
  • Renal lobe
    ÄáÆÏ¿±
    [¿¾ ¿ë¾î] ½ÅÀå¼Ò¿±
  • Renal lobes
    ÄáÆÏ¿±
    [¿¾ ¿ë¾î] ½Å¿±
  • Renal papilla
    ÄáÆÏÀ¯µÎ
    [¿¾ ¿ë¾î] ½ÅÀ¯µÎ
  • Renal papillae
    ÄáÆÏÀ¯µÎ
    [¿¾ ¿ë¾î] ½ÅÀ¯µÎ
  • Renal impression
    ÄáÆÏÀÚ±¹
    [¿¾ ¿ë¾î] ½Å¾ÐÈç
  • Renal veins
    ÄáÆÏÁ¤¸Æ
    [¿¾ ¿ë¾î] ½ÅÁ¤¸Æ
  • Renal tissue (Nephroblastoma)
    ÄáÆÏÁ¶Á÷ (ÄáÆÏ¸ð¼¼Æ÷Á¾)
    [¿¾ ¿ë¾î] ½ÅÁ¶Á÷
  • Renal pyramid
    ÄáÆÏÇǶó¹Ô
    [¿¾ ¿ë¾î] ½ÅÃßü
  • Renal pyramids
    ÄáÆÏÇǶó¹Ô
    [¿¾ ¿ë¾î] ½ÅÃßü
  • Renal capsule
    ÄáÆÏÇǸ·
    [¿¾ ¿ë¾î] ½ÅÇǸ·
  • Renal blood vessel
    ÄáÆÏÇ÷°ü
    [¿¾ ¿ë¾î] ½ÅÀåÇ÷°ü
  • Major renal calices
    Å«(ÄáÆÏ)¼úÀÜ
    [¿¾ ¿ë¾î] ´ë½Å¹è
  • Base of renal pyramid
    ÇǶó¹Ô¹Ù´Ú
    [¿¾ ¿ë¾î] ÃßüÀú
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • renal rickets
    ½Å¼º ±¸·çº´
  • renal scanning
    ½ÅÁÖ»ç¹ý
  • renal scintigraphy
    ½Å½ÃƼ±×·¡ÇÇ
  • renal transplantation
    ½ÅÀ̽Ä
  • renal tubular acidosis
    ½Å´¢¼¼°ü»êÁõ
  • renal vein
    ½ÅÁ¤¸Æ
  • renal vein thrombosis
    ½ÅÁ¤¸ÆÇ÷ÀüÁõ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MDII Multiple Daily Insulin Injections
MEDAC Syndrome Multiple-Endocrine Deficiency Autoimmune-Candidiasis
MM Multiple Myeloma
MS   1) Mitral Stenosis
  2) Multiple Sclerosis; ´Ù¹ß¼º °æÈ­Áõ
  3) Macro...
MSLT Multiple Sleep Latency Test
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
MAP Multiple Antigen Peptide
MAP Multiple Antigenic Peptide
MCS Multiple Chemical Sensitivities
MCS Multiple Chemical Sensitivity
MCQ multiple choice question
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • multiple papilloma
    ´Ù¹ß¼º À¯µÎÁ¾
  • multiple petechia
    ´Ù¹ß¼º Á¡»ó ÃâÇ÷
  • multiple photoreceptor
    ´Ù¹ß¼º ±¤ ¼ö¿ëü, ´Ù¹ß¼º ±¤ ¼ö¿ë±â
  • multiple projection
    ´Ù¹ß¼º Á¶»ç
  • multiple pulmonary emboli
    ´Ù¹ß¼º Æó »öÀü
  • multiple region
    ´Ù¹ß¼º ºÎÀ§
  • multiple rough gravellike sound
    ´Ù¹ß¼ºÀÇ °ÅÄ£ ÀÚ°¥ °¡´Â ¼Ò¸®
  • multiple seborrheic keratoses
    ´Ù¹ß Áö·ç¼º °¢È­Áõ
  • multiple sinus fracture
    ´Ù¹ß¼º ºÎºñµ¿ °ñÀý
  • multiple somatic receptor
    ´Ù¹ß¼º ü ¼ö¿ëü, ´Ù¹ß¼º ü ¼ö¿ë±â
  • multiple spike
    ´Ù¹ß¼º ½ºÆÄÀÌÅ©
  • multiple surgical procedure
    ´Ù¹ß¼º ¿Ü°úÀû Ä¡·á
  • multiple vascular tumor
    ´Ù¹ß¼º Ç÷°ü Á¾¾ç
  • multiple wart
    ´Ù¹ß¼º »ç¸¶±Í
  • multiple-loop wiring
    ¿¬¼Ó Ä¡¾Æ °áÂû¹ý
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
multiple cloning site Region of a phage or plasmid vector that has been engineered to contain a series of restriction sites that are usually unique within the entire vector. This makes it particularly easy to insert or excise (subclone) DNA fragments.
(18 Nov 1997)
multiple drug resistant tuberculosis A strain of TB that does not respond to two or more standard anti-TB drugs. MDR-TB usually occurs when treatment is interrupted thus allowing mutations in the organism to occur that confer drug resistance.
(09 Oct 1997)
multiple ego states Various psychological organizational state's reflecting different personas or life experiences.
(05 Mar 2000)
multiple embolism Embolism caused by the arrest of a number of small emboli.
(05 Mar 2000)
multiple endocrine adenomatosis The presence of functioning tumours in more than one endocrine gland, commonly the pancreatic islets and parathyroid glands, which may be associated with Zollinger-Ellison syndrome; dominant inheritance.
Synonym: multiple endocrine adenomatosis.
(05 Mar 2000)
multiple endocrine deficiency syndrome <syndrome> Acquired deficiency of the function of several endocrine glands, usually on an auto-immune basis.
Synonym: multiple glandular deficiency syndrome.
(05 Mar 2000)
multiple endocrine neoplasia (type I) This is a hereditary disorder in which two or more of the following glands: parathyroid, pancreas, pituitary, adrenals or thyroid develop hyperplasia or a tumour.
(type II) This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
Origin: Gr. Plassein = to form
(27 Sep 1997)
multiple endocrine neoplasia 1 <radiology> Multiple endrocrine neoplasia syndrome three P's.
Pituitary adenoma, 65% can develop Cushing's, acromegaly, prolactinoma, parathyroid hyperplasia / adenoma, 88% can develop hyper-PTH
pancreatic isleT-cell tumour, gastrinoma (Z-E) most common, 50% of Z-E can develop MEN-1, inconstant features: bronchial/intestinal carcinoid, thyroid adenoma, adrenal cortical tumour, lipoma, thymoma tissue expression
Primary hyperparathyroidism (90%), Gastrinoma (30%), Prolactinoma (15%), Other (10%).
Synonym: Wermer syndrome
(12 Dec 1998)
multiple endocrine neoplasia 2 <radiology> Multiple endocrine neoplasia syndrome, medullary thyroid carcinoma, usually multifocal; metastasis to local nodes, lung, liver, usually calcify in liver, pheochromocytoma, almost always bilateral, parathyroid hyperplasia, may be secondary to calcitonin secreted by medullary thyroid carcinoma inconstant feature: adrenal cortical hyperplasia
Synonym: Sipple syndrome
(12 Dec 1998)
multiple endocrine neoplasia 3 <radiology> Multiple endocrine neoplasia syndrome (type 2B, type 3), medullary thyroid carcinoma, pheochromocytoma, marfanoid habitus (Cf: Marfan syndrome), mucosal neuromas, neurofibromas, ganglioneuromatosis coli More info: MEN syndrome 2B
Synonym: Schimke, marfanoid syndrome
(12 Dec 1998)
multiple endocrine neoplasia type 1 A rare syndrome characterised by hyperplasia and/or neoplasms of the pituitary, parathyroid glands, and pancreatic islets. Hyperparathyroidism occurs in 90% of the cases and is usually the first manifestation of the syndrome. The most frequent pancreatic manifestation is gastrinoma typically leading to zollinger-ellison syndrome. The appearance of this condition has been limited to the loss of allelic heterozygosity at the 11q13 locus on the long arm of chromosome 11. Patients overall exhibit long survival times. Chemotherapy is rare and surgical management is generally dependent on the genetic expression in individual patients.
(12 Dec 1998)
multiple endocrine neoplasia type 2 <syndrome> This is a hereditary disorder in which two or more of the following glands: thyroid, adrenal or parathyroid, develop overgrowth (hyperplasia) or malignant cells (cancer). The underlying cause is genetic and a positive family history for this illness is a risk factor.
Incidence: approximately 3 in 100,000 people in the general population.
(27 Sep 1997)
multiple endocrine neoplasia type 2a A type of multiple endocrine neoplasia characterised by a virtually 100% incidence of medullary thyroid carcinoma, a 50% incidence of pheochromocytoma, and a lesser incidence of parathyroid adenomas associated with hyperparathyroidism. The condition is always transmitted through autosomal dominant inheritance. Genetic testing can identify individuals with the trait in early infancy. Treatment is usually excision of the enlarged parathyroid glands.
(12 Dec 1998)
multiple endocrine neoplasia type 2b A type of multiple endocrine neoplasia occurring as an isolated congenital presentation or as a distinct autosomal dominant disease. It is characterised by the 100% incidence of medullary thyroid carcinoma and frequent pheochromocytomas; patients seldom exhibit hyperparathyroidism. It is distinguished from men 2a by its characteristic physical appearance resulting from numerous neural defects including mucosal neuromas of the eyelids, lips, and tongue. The neural abnormalities also include widespread neurogangliomatosis of the gastrointestinal tract leading to abnormal gut motility. Treatment usually requires total thyroidectomy following evaluation for the presence of pheochromocytomas.
(12 Dec 1998)
multiple epiphysial dysplasia A dominantly inherited abnormality of epiphyses characterised by difficulty in walking, pain and stiffness of joints, stubby fingers, and often dwarfism of short-limb type; on X-ray examination, the epiphyses are mottled and irregular; ossification centres are late in appearance and may be multiple, but the vertebrae are normal. There is also an autosomal recessive form .
Synonym: dysplasia epiphysialis multiplex.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á